Curasan AG operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Curasan AG with three other
pharmaceutical manufacturers in Europe:
Pure Biologics SA
of POLAND
(2019
sales of 16.75 million Polish New Zlotys [US$4.45 million]
),
Erytech Pharma SA
of FRANCE
(5.28 million Euros [US$6.24 million]
of which 100%
was Pharmacy), and
CO.DON AG
(6.86 million Euros [US$8.10 million]
of which 100%
was Product sales).
Sales Analysis.
Curasan AG reported sales of 6.20 million Euro (US$7.33 million)
for the
year ending
December of 2019.
This
represents
an
increase of 6.1%
versus 2018, when the company's sales were 5.84 million Euro.
Despite this increase, sales are still
below the level achieved in 2017, when Curasan AG
reported sales of 6.80 million Euro.
The sales level in 2019 was fairly close to the level five years ago: in 2014, Curasan AG had sales
of 5.99 million Euro.